Investor Presentaiton
Investor presentation
Full year 2018
Slide 33
Million
400
Region AAMEO at a glance
Diabetes trend in population
Population with diabetes
Diabetes growth rate
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
NN Insulin MS
NN OAD MS
bDKK
24
NN GLP-1 MS
Full year 2018
Sales
(MDKK)
Growth²
80%
85%
Long-acting insulin³
1,281
16%
GLP-1
Premix insulin4
2,606
9%
I
346
24.2%1
300
- 60%
Insulin
Fast-acting insulin5
2,194
10%
16
Human insulin
2,065
14%
200
368%
4.1%¹
40%
Total insulin
8,146
11%
187
GLP-16
841
6%
8
100
20%
11.3%1
OAD
Other diabetes care?
Diabetes care
675
(3%)
9,662
10%
40
0
0
2000
2017
2045
Nov
2013
Obesity (SaxendaⓇ)
418
136%
0%
Nov
2018
Biopharm³
2,073
6%
Total
12,153
11%
AAMEO: Africa, Asia, the Middle-East and Oceania
AAMEO population 2018: ~4.3 billion people and diabetes prevalence
~7.5%
Source: International Diabetes Federation: Diabetes Atlas 1st Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share comparison for insulin as of Nov 2018:
Novo Nordisk 52%, Sanofi 31% and Eli Lilly 11%
Competitor value market share comparison for GLP-1 as of Nov 2018:
Novo Nordisk 43%, AstraZeneca 30% and Eli Lilly 27%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Nov, 2018 value figures
2 Percentage change in local currency from full year 2017 to full year
2018
3 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 4 Comprises NovoMix®
and RyzodegⓇ; 5 Comprises NovoRapidⓇ; 6 Comprises VictozaⓇ;
7 Comprises NovoNorm® and needles; 8 Comprises primarily
NovoSeven®, NovoEight® NovoThirteenⓇ, Norditropin®, VagifemⓇ and
Activelle®View entire presentation